Is Sanofi's Stock a Buy?
Investors looking for a large-cap pharmaceutical investment have a number of options to choose from. One of them is Sanofi (NASDAQ: SNY), a company with a fairly diverse drug portfolio that has been getting plenty of attention due to its diabetes treatments, a market that's especially lucrative right now.
Despite an earlier piece of bad news from the U.S. Food and Drug Administration (FDA) rejecting one of Sanofi's diabetes drugs, prospects for the company now look better following some new clinical results. Let's go into some of the details surrounding Sanofi's drug candidates, how the company looks overall, and whether investors should consider adding Sanofi to their portfolios.
Image source: Getty Images.
Source Fool.com
